Seeking Alpha28/09/2026 22:17:27

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow

By SA Transcripts
1 day ago
View Original Source
Seeking Alpha

Seeking Alpha

Seeking Alpha is the leading platform for investors to research and discuss US-traded stocks and ETFs. Our platform helps investors to find successful investing ideas and to successfully manage their portfolios. It provides investment ideas, analysis, news, ratings, investing tools and community discussion.

More from Seeking Alpha

AMD: Why I Say 80x Forward P/E Doesn't Matter This Time

10 min ago

C3is GAAP EPS of $162.59, revenue of $35.62M

11 min ago

Weekly ETFs: Eight of 11 sectors record inflows; gold leads outflows

12 min ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

12 min ago